Emerging Therapeutic Approaches in Women's Reproductive Health: Current Advances in Fertility Enhancement and Management
article
OA: green
CC0
Abstract
Infertility remains a significant challenge in women’s reproductive health, necessitating the development of innovative therapeutic strategies. Advances in pharmacological interventions, including hormonal therapies like clomiphene citrate, gonadotropins, and letrozole, have improved ovulatory function and pregnancy rates. Assisted reproductive technologies (ARTs), such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), continue to evolve with the integration of artificial intelligence (AI) for embryo selection and optimization of implantation success. Additionally, targeted drug therapies, including metformin for polycystic ovary syndrome (PCOS) and progesterone for luteal phase support, play a critical role in fertility enhancement. Beyond pharmacological approaches, nutraceuticals and dietary interventions offer promising avenues for fertility management.Antioxidants such as Coenzyme Q10 (CoQ10), vitamin D, and omega-3 fatty acids help mitigate oxidative stress, while plant-based bioactives, including flavonoids and polyphenols, contribute to improved ovarian function. The role of probiotics in modulating gut and vaginal microbiota is increasingly recognized, with specific strains like Lactobacillus crispatus and Lactobacillus rhamnosus demonstrating potential in improving reproductive outcomes. Regenerative medicine, including mesenchymal stem cell (MSC) therapy and gene editing technologies such as CRISPR, offers cutting-edge solutions for ovarian rejuvenation and endometrial repair. These emerging interventions hold promise in addressing age-related infertility and conditions like premature ovarian insufficiency (POI). The influence of microbiome dysbiosis on reproductive disorders, including endometriosis and PCOS, underscores the need for microbiome-targeted therapies. Furthermore, technological advancements in reproductive medicine include artificial gametes derived from induced pluripotent stem cells (iPSCs), uterine transplantation, and bioengineered reproductive tissues, expanding the possibilities for fertility preservation and treatment. However, these innovations come with ethical concerns, regulatory challenges, and potential risks that require further exploration. This review highlights the multifaceted landscape of fertility enhancement strategies, integrating pharmacological, nutritional, regenerative, and technological interventions. Future research should focus on personalized reproductive medicine, addressing individual patient needs and optimizing therapeutic efficacy.
Full text
2,850 characters
· extracted from
oa-doi-fallback
· click to expand
Emerging Therapeutic Approaches in Women's Reproductive Health: Current Advances in Fertility Enhancement and Management
Description
Infertility remains a significant challenge in women’s reproductive health, necessitating the development of innovative therapeutic strategies. Advances in pharmacological interventions, including hormonal therapies like clomiphene citrate, gonadotropins, and letrozole, have improved ovulatory function and pregnancy rates. Assisted reproductive technologies (ARTs), such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), continue to evolve with the integration of artificial intelligence (AI) for embryo selection and optimization of implantation success. Additionally, targeted drug therapies, including metformin for polycystic ovary syndrome (PCOS) and progesterone for luteal phase support, play a critical role in fertility enhancement. Beyond pharmacological approaches, nutraceuticals and dietary interventions offer promising avenues for fertility management.Antioxidants such as Coenzyme Q10 (CoQ10), vitamin D, and omega-3 fatty acids help mitigate oxidative stress, while plant-based bioactives, including flavonoids and polyphenols, contribute to improved ovarian function. The role of probiotics in modulating gut and vaginal microbiota is increasingly recognized, with specific strains like Lactobacillus crispatus and Lactobacillus rhamnosus demonstrating potential in improving reproductive outcomes. Regenerative medicine, including mesenchymal stem cell (MSC) therapy and gene editing technologies such as CRISPR, offers cutting-edge solutions for ovarian rejuvenation and endometrial repair. These emerging interventions hold promise in addressing age-related infertility and conditions like premature ovarian insufficiency (POI). The influence of microbiome dysbiosis on reproductive disorders, including endometriosis and PCOS, underscores the need for microbiome-targeted therapies. Furthermore, technological advancements in reproductive medicine include artificial gametes derived from induced pluripotent stem cells (iPSCs), uterine transplantation, and bioengineered reproductive tissues, expanding the possibilities for fertility preservation and treatment. However, these innovations come with ethical concerns, regulatory challenges, and potential risks that require further exploration. This review highlights the multifaceted landscape of fertility enhancement strategies, integrating pharmacological, nutritional, regenerative, and technological interventions. Future research should focus on personalized reproductive medicine, addressing individual patient needs and optimizing therapeutic efficacy.
Files
128-Manjari.pdf
Files
(640.0 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:29e6f2b041bac3ba7cacbd49f922a42a
|
640.0 kB | Preview Download |
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Ask this paper
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- openalex
- last seen: 2026-05-10T10:36:44.016912+00:00
License: CC0
· commercial use OK